PURPOSE: To describe rifabutin-associated uveitis with opacities in the inferior and posterior vitreous in three patients with acquired immunodeficiency syndrome. METHOD: Case reports of the three patients are presented. RESULTS: The patients, who were being treated with rifabutin and fluconazole, developed anterior and posterior uveitis. The posterior uveitis was characterized by white-yellow inflammatory opacities located in the inferior and posterior vitreous. Discontinuation of rifabutin and the start of topical corticosteroid therapy resulted in improvement of the uveitis and visual acuity. CONCLUSION: Recognition of rifabutin-associated uveitis with opacities in the inferior and posterior vitreous may prevent unnecessary invasive diagnostic and therapeutic procedures.
PURPOSE: To describe rifabutin-associated uveitis with opacities in the inferior and posterior vitreous in three patients with acquired immunodeficiency syndrome. METHOD: Case reports of the three patients are presented. RESULTS: The patients, who were being treated with rifabutin and fluconazole, developed anterior and posterior uveitis. The posterior uveitis was characterized by white-yellow inflammatory opacities located in the inferior and posterior vitreous. Discontinuation of rifabutin and the start of topical corticosteroid therapy resulted in improvement of the uveitis and visual acuity. CONCLUSION: Recognition of rifabutin-associated uveitis with opacities in the inferior and posterior vitreous may prevent unnecessary invasive diagnostic and therapeutic procedures.